MarketPulse

retinal disease

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Ocular Therapeutix Plans June Investor Day Amid Promising AMD Trial Data

Ocular Therapeutix schedules June 17 investor day in NYC while reporting positive Week 52 data from SOL-1 Phase 3 trial of AXPAXLI for wet AMD treatment.
OCULPhase 3 trialInvestor Day
GlobeNewswire Inc.GlobeNewswire Inc.··Belite Bio, Inc

Belite Bio Pursues FDA Approval for Tinlarebant, Potential First Stargardt Disease Treatment

Belite Bio begins rolling NDA submission to FDA for tinlarebant, a potential breakthrough oral therapy for rare Stargardt disease, targeting 2027 commercialization.
BLTEFDA approvalrare disease
BenzingaBenzinga··Globe Newswire

MeiraGTx Acquires Johnson & Johnson's Gene Therapy for Rare Blindness

MeiraGTx acquires J&J's bota-vec gene therapy for rare blindness in $25M deal, targeting 2027 launch with promising Phase 3 clinical data.
JNJMGTXFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Eyepoint, Inc.

EyePoint Pharmaceuticals Names Veteran Ophthalmology Executive Campbell as CCO

EyePoint Pharmaceuticals appoints Michael Campbell as Chief Commercial Officer. The ophthalmology veteran brings 30+ years of experience to lead commercial strategy for DURAVYU ahead of 2026 clinical data.
EYPTPhase 3 clinical trialophthalmology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ocular Therapeutix to Release SOL-1 Phase 3 Results for Wet AMD Treatment

Ocular Therapeutix announces Phase 3 results for SOL-1 wet AMD treatment on February 17, 2026. AXPAXLI data presentation follows at Macula Society Annual Meeting.
OCULPhase 3 clinical trialbiopharmaceutical